The Freeland File
Aerospace & Defense
Global Market Data
Lucy P. Marcus
David Cay Johnston
The Great Debate
Jack & Suzy Welch
Macro & Markets
Lipper Awards 2012
Personal Finance Video
Our best photos from the last 24 hours. Slideshow
Images of September
Venezuela's Chavez revels in re-election victory
Pressure is on Biden after Obama's lackluster debate performance
07 Oct 2012
Chavez supporters party on anticipated win in Venezuela vote
07 Oct 2012
Alwaleed's Kingdom Holding plans up to $500 mln loan - sources
07 Oct 2012
Lawmakers seek to block China's Huawei, ZTE inroads in U.S.
Romney’s strong debate showing puts Europe on edge
Obama and Romney battle over economy at debate
Weak U.S. labor market looms ahead of elections
Our day's top images, in-depth photo essays and offbeat slices of life. See the best of Reuters photography. See more | Photo caption
Hugo Chavez scored a comfortable election victory over Henrique Capriles, that could extend his rule to 20 years. Slideshow
David Blaine electrifies
Magician David Blaine stands on a 20-foot-high platform, channeling one million volts of electricity through tesla coils for 72 hours. Slideshow
UK, Japan scientists win Nobel for adult stem cell discovery
A look at the Nobel Medicine Prize
Stem cell work wins Nobel prize
1 of 7. Kyoto University Professor Shinya Yamanaka (L) and John Gurdon of the Gurdon Institute in Cambridge are seen at a symposium on induced pluripotent stem cell in Tokyo, in this photo taken by Kyodo on April 2008.
By Anna Ringstrom
Mon Oct 8, 2012 11:27am EDT
STOCKHOLM (Reuters) - Scientists from Britain and Japan shared a Nobel Prize on Monday for the discovery that adult cells can be transformed back into embryo-like stem cells that may one day regrow tissue in damaged brains, hearts or other organs.
John Gurdon, 79, of the Gurdon Institute in Cambridge, Britain and Shinya Yamanaka, 50, of Kyoto University in Japan, discovered ways to create tissue that would act like embryonic cells, without the need to collect the cells from embryos.
They share the $1.2 million Nobel Prize for Medicine, for work Gurdon began 50 years ago and Yamanaka capped with a 2006 experiment that transformed the field of "regenerative medicine" - the search for ways to cure disease by growing healthy tissue.
"These groundbreaking discoveries have completely changed our view of the development and specialization of cells," the Nobel Assembly at Stockholm's Karolinska Institute said.
All of the body starts as stem cells, before developing into tissue like skin, blood, nerves, muscle and bone. The big hope is that stem cells can grow to replace damaged tissue in cases from spinal cord injuries to Parkinson's disease.
Scientists once thought it was impossible to turn adult tissue back into stem cells. That meant new stem cells could only be created by taking them from embryos, which raised ethical objections that led to research bans in some countries.
As far back as 1962 Gurdon became the first scientist to clone an animal, making a healthy tadpole from the egg of a frog with DNA from another tadpole's intestinal cell. That showed that developed cells carry the information to make every cell in the body - decades before other scientists made world headlines by cloning the first mammal from adult DNA, Dolly the sheep.
More than 40 years later, Yamanaka produced mouse stem cells from adult mouse skin cells by inserting a small number of genes. His breakthrough effectively showed that the development that takes place in adult tissue could be reversed, turning adult tissue back into cells that behave like embryos.
Stem cells created from adult tissue are known as "induced pluripotency stem cells", or iPS cells. Because patients may one day be treated with stem cells from their own tissue, their bodies might be less likely to reject them.
"The eventual aim is to provide replacement cells of all kinds," Gurdon's institute explains on its website.
"We would like to be able to find a way of obtaining spare heart or brain cells from skin or blood cells. The important point is that the replacement cells need to be from the same individual, to avoid problems of rejection and hence of the need for immunosuppression."
In just six years, Yamanaka's paper has already been cited more than 4,000 times in other scientists' work.
In a news conference in Japan, he thanked his team of young researchers: "My joy is very great. But I feel a grave sense of responsibility as well."
Gurdon spoke of his own unlikely career as a young man who loved science but was steered away from it at school, only to take it up again at university.
He still keeps an old school report in a frame on his desk: "I believe he has ideas about becoming a scientist... This is quite ridiculous," his teacher wrote. "It would be a sheer waste of time, both on his part and of those who have to teach him."
The science of iPS cells is still in early stages. Among concerns is the fear that implanted cells could grow out of control and develop into tumors.
Some scientists say stem cells from embryos may prove more useful against disease than iPS cells, and the ethics of working with embryos should be defended.
Nevertheless, since Yamanaka published his findings the discoveries have already produced advances. The techniques are being used to grow cells in laboratories to study disease, the chairman of the awards committee, Urban Lendahl, told Reuters.
"You can't take out a large part of the heart or the brain or so to study this, but now you can take a cell from, for example, the skin of the patient, reprogramme it, return it to a pluripotent state, and then grow it in a laboratory," he said.
"The second thing is for further ahead. If you can grow different cell types from a cell from a human, you might - in theory for now but in future hopefully - be able to return cells where cells have been lost."
Thomas Perlmann, Nobel Committee member and professor of Molecular Development Biology at the Karolinska Institute said: "Thanks to these two scientists, we know now that development is not strictly a one-way street."
"There is lot of promise and excitement, and difficult disorders such as neurodegenerative disorders, like perhaps Alzheimer's and, more likely, Parkinson's disease, are very interesting targets."
For now, both men said their scientific work continues.
Asked why he still keeps his schoolteacher's discouraging report, Gurdon said: "When you're having problems, like when an experiment doesn't work - which often happens - it's nice to remind yourself that perhaps after all you're not so good at this job and the schoolmaster may have been right."
(Reporting by Patrick Lannin, Alistair Scrutton, Ben Hirschler, Kate Kelland, Kiyoshi Takenaka, Chris Wickham and Peter Graff; writing by Peter Graff; editing by Philippa Fletcher)
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Back to top
New York Legal
Support & Contact
Connect with Reuters
Our Flagship financial information platform incorporating Reuters Insider
An ultra-low latency infrastructure for electronic trading and data distribution
A connected approach to governance, risk and compliance
Our next generation legal research platform
Our global tax workstation
About Thomson Reuters
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.